Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial | Zendy

Sotaro Sadahiro | Zendy; Toshiyuki Suzuki | Zendy; Kazutake Okada | Zendy; Gota Saito | Zendy; Hiroshi Miyakita | Zendy; Takashi Ogimi | Zendy; Lin Fung Chan | Zendy; Yutaro Kamei | Zendy

Open Access

Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial

Author(s) -

Sotaro Sadahiro,

Toshiyuki Suzuki,

Kazutake Okada,

Gota Saito,

Hiroshi Miyakita,

Takashi Ogimi,

Lin Fung Chan,

Yutaro Kamei

Publication year - 2020

Publication title -

oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.987

H-Index - 98

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000507293

Subject(s) - bevacizumab , irinotecan , medicine , folfiri , clinical endpoint , colorectal cancer , fluorouracil , chemotherapy , phases of clinical research , gastroenterology , surgery , randomized controlled trial , cancer

FOLFIRI plus bevacizumab have been widely used as first-line treatment for metastatic colorectal cancer (mCRC). Pharmacokinetics and pharmacodynamics suggested a low dose of irinotecan given as a long-term infusion is expected to enhance antitumor activity. We conducted a randomized phase II study to compare oral S-1 with a 24-h infusion of irinotecan plus bevacizumab versus FOLFIRI plus bevacizumab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research